eli lilly clinical trials retatrutide Lilly's triple agonist delivers up to 71.2 lbs of weight loss Seeking Differentiation Through a Triple

Overall, our data suggest that females show reduced glucose-lowering benefit from GLP1-M treatment Table 4)

Clinical effects of GLP-1 agonists on weight and diet

However, there may be limitations in treating comorbid conditions like sleep-related breathing disorders

Regulatory & Safety Status in South Africa Retatrutide is not approved for sale as a finished medicine by SAHPRA, the FDA, or the EMA as of 2026

MEDVi uses temperature-controlled packaging, which matters significantly for peptide medications that require refrigeration

Lab Testing: What Gets Measured and Why It Matters Found does not routinely require labs, but providers may order them if your health history raises concerns